

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2015 OS PC

DESPATCHED ON 24TH MARCH 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A24; B7, B8; Cw7,-; DR4, DR17; DQ2, DQ8

			Summary of Results							
			PBL/T-Cells				B-Cells			
Total tested			29	29	29	29	22	22	22	22
Positive			0	3	1	1	0	2	5	7
Negative			29	26	28	28	22	20	17	15
NT/Equivocal			4	4	4	4	2	2	2	2
% Positive			0.0%	10.3%	3.4%	3.4%	0.0%	9.1%	22.7%	31.8%
% Negative			100.0%	89.7%	96.6%	96.6%	100.0%	90.9%	77.3%	68.2%
Consensus			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed
HLA Antibody Specificity (Defined By CDC)			DQ1	A9, DR15	DQ3	A2, B17	DQ1	A9, DR15	DQ3	A2, B17
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Without DTT		Serum 4	Serum 1	Without DTT		Serum 4
112	YES	NO	Negative	Negative	Negative	Negative				
116	YES	NO	Negative	Negative	Positive	Negative				
119	YES	NO	Negative	Positive	Negative	Positive				
120	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive
128	YES	NO	Negative	Negative	Negative	Negative				
139	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive
143	YES	NO	Negative	Negative	Negative	Negative				
147	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive
154	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
157	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Weak Positive
159	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
174	YES	NO	NT	NT	NT	NT				
181	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive
189	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
190	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
193	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
195	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
197	YES	YES	NT	NT	NT	NT	Negative	Negative	Positive	Negative
209	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
216	YES	NO	Negative	Negative	Negative	Negative				
223	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT
229	YES	NO	Negative	Negative	Negative	Negative				
232	YES	NO	NT	NT	NT	NT				
238	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive
245	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
252	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
259	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
260	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
262	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive
293	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
294	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
297	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative

Poor cell viability

No results returned

Poor T cell viability

Poor B cell viability

Poor cell viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A03/2015 OS PC

DESPATCHED ON 24TH MARCH 2015

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	-1	-2	-1	-1					90		
116	1	1	2	1						90	
119	1	6	1	4					85		
120	1	1	1	1	1	1	4	4		100	100
128	1	1	1	1					80		
139	1	4	1	1	1	4	6	6	80	80	80
143	2	2	2	2						90	
147	1	1	1	1	1	1	1	8		100	100
154	1	1	1	1	1	1	1	1		95	95
157									100	100	100
159	1	1	1	1	1	1	1	1		100	100
174	NT	NT	NT	NT							
181	1	1	1	1	1	1	2	4	85		85
189	1	1	1	1	1	1	1	1	90	90	88
190	2%	2%	2%	2%	5%	5%	20%	20%		98	95
193	1	1	1	1	1	1	1	1		99	95
194	1	1	1	1	1	1	1	1	100	98	98
195											
197	NT	NT	NT	NT			Moderate		80	50	70
209										95	95
216	2	2	2	2					80		
223	1	1	1	1	NT	NT	NT	NT		90	60
229									90		
232	NT	NT	NT	NT					20		
238	1	2	1	1	1	4	6	6	90	80	60
245	1	1	1	1	1	1	1	1	100	100	100
252	1	1	1	1	1	1	1	1	40		30
259									90	90	90
260										90	80
262							8	8	100	100	100
293										70	60
294	0	0	0	0	2	2	2	2		95	95
297	1	1	1	1	1	1	1	1	80	80	80

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2015 OS PC

DESPATCHED ON 24TH MARCH 2015

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A24; B7, B8; Cw7,-; DR4, DR17; DQ2, DQ8

			Summary of Results							
			PBL/T-Cells				B-Cells			
Total tested			23	23	23	23	20	20	20	20
Positive			0	3	0	0	0	2	5	3
Negative			23	20	23	23	20	18	15	17
NT/Equivocal			4	4	4	4	2	2	2	2
% Positive			0.0%	13.0%	0.0%	0.0%	0.0%	10.0%	25.0%	15.0%
% Negative			100.0%	87.0%	100.0%	100.0%	100.0%	90.0%	75.0%	85.0%
Consensus			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
HLA Antibody Specificity (Defined By CDC)			DQ1	A9, DR15	DQ3	A2, B17	DQ1	A9, DR15	DQ3	A2, B17
Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT			
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4
112	YES	NO	Negative	Negative	Negative	Negative				
116	YES	NO	Negative	Negative	Negative	Negative				
119	YES	NO	Negative	Positive	Negative	Negative				
120	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive
139	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive
147	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
154	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
157	NO	YES					Negative	Negative	Negative	Negative
159	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
174	YES	NO	NT	NT	NT	NT				
181	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
189	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
190	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
193	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
194	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
195	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT
197	YES	YES	NT	NT	NT	NT	Negative	Negative	Positive	Negative
209	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
216	YES	NO	Negative	Negative	Negative	Negative				
229	YES	NO	Negative	Negative	Negative	Negative				
238	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive
245	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
252	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
260	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
262	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative
293	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
294	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
297	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative

Low cell count

Poor cell viability

No results returned

Poor T cell viability

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A03/2015 OS PC

DESPATCHED ON 24TH MARCH 2015

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
112	-1	-2	-1	-1					90		
116	1	1	1	1						90	
119	1	2	1	1					85		
120	1	1	1	1	1	1	4	4		100	100
139	1	4	1	1	1	4	6	6	80	80	80
147	1	1	1	1	1	1	1	1		100	100
154	NT	NT	NT	NT	NT	NT	NT	NT		95	95
157									100	100	100
159	1	1	1	1	1	1	1	1		100	100
174	NT	NT	NT	NT							
181	1	1	1	1	1	1	1	2	85		85
189	1	1	1	1	1	1	1	1	90	90	88
190	2%	2%	2%	2%	10%	10%	10%	10%		98	95
193	1	1	1	1	1	1	1	1		99	95
194	1	1	1	1	1	1	1	1	100	98	98
195											
197	NT	NT	NT	NT			Moderate		80	50	70
209										95	95
216	2	2	2	2					80		
229									90		
238	1	2	1	1	1	2	4	2	90	80	60
245	1	1	1	1	1	1	1	1	100	100	100
252	1	1	1	1	1	1	1	1	40		30
260										90	80
262							6		100	100	100
293										70	60
294	0	0	0	0	0	2	2	2		95	95
297	1	1	1	1	1	1	1	1	80	80	80